MedTrace Logo

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

NCT02452268 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2023-03-03

No results posted yet for this study

Summary

Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion

Conditions

  • Metastatic and Advanced Solid Tumors

Interventions

DRUG

NIZ985

Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks

DRUG

PDR001

• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-08
Primary Completion
2022-03-07
Completion
2022-03-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452268 on ClinicalTrials.gov